共查询到18条相似文献,搜索用时 175 毫秒
1.
17例恶性肿瘤18氟脱氧葡萄糖PET显像假阴性的分析 总被引:3,自引:0,他引:3
目的 探讨恶性肿瘤^18氟脱氧葡萄糖(^18F—FDG)PET假阴性患者的FDG摄取特点、影响因素,分析PET/CT检查中CT对其的辅助诊断价值。方法 收集行PET/CT检查者中,^18F-FDGPET为阴性的17例恶性肿瘤患者,对其PET图像进行视觉观察和半定量分析,并与CT及病理检查结果进行对比分析。结果 6例肝癌患者病理证实为高分化型肝细胞肝癌,其中1例有两处病灶,一处病灶FDG摄取、平扫CT密度较周围正常肝组织低下,另一处病灶FDG摄取、平扫CT均为阴性;后行增强CT显示在动脉期两处病灶均明显强化。1例胃印戒细胞癌伴右侧附件转移患者,1例腹壁、大网膜转移性腺癌患者,3例肾透明细胞癌患者和1例前列腺癌患者(高分化型)的^18F—FDGPET诊断受消化道正常生理性FDG摄取或泌尿系统FDG滞留的影响。3例转移癌病变直径≤1cm,其中2例的原发病灶FDG摄取明显增高,1例原发病灶^18F—FDGPET及CT诊断为阴性。68.8%原发肿瘤、66.7%转移肿瘤在平扫CT上显示异常密度,并精确定位;而31.2%原发肿瘤、33.3%转移肿瘤病变^18 F—FDGPET及CT诊断均为阴性。结论恶性肿瘤^18F—FDGPET假阴性与病理学类型、分化程度及病灶大小有关;结合CT或重视PET显像方法可减少恶性肿瘤^18F—FDGPET假阴性。 相似文献
2.
18F-FDG双探头符合显像与99mTc-MDP显像在探测恶性肿瘤骨转移中的应用 总被引:1,自引:0,他引:1
目的比较双探头带符合线路SPECT仪^18F-脱氧葡萄糖(FDG)显像和^99m Tc-亚甲基二膦酸盐(MDP)显像对恶性肿瘤骨转移病灶的探测效果。方法各种恶性肿瘤患者37例,分别行^18F—FDG胸腹部显像和^99m Tc—MDP全身骨显像。比较脊柱、肋骨和骨盆等部位骨骼的病变情况。结果^18F-FDG显像和^99mTc—MDP显像共发现骨骼病灶130处,其中^18F—FDG显像共发现121处(93.1%),^99mTc—MDP显像共发现120处(92.3%),两者共同发现114处(87.7%);仅^18F—FDG显像发现而^99mTc—MDP显像未发现有11处,仅^99mTc—MDP显像发现而^18F—FDG显像未发现有10处。37例患者中,两种方法共检出有骨转移者24例,其中^18F—FDG显像发现23例,^99mTc—MDP显像发现2z例,^18F-FDG显像和^99mTc—MDP显像完全相符有15例,不符有9例。^18F—FDG显像发现有远处转移者32例。结论^18F—FDG双探头符合显像与^99mTc-MDP显像在探测恶性肿瘤骨转移病灶上具有相同的敏感性,但两者在某些病灶的探查上具有互补作用。 相似文献
3.
目的评价18F—FDGPET—CT在检测NSCLC骨转移中的应用价值。方法回顾性分析18F-FDGPET.CT扫描的NSCLC患者362例,按颈椎、胸椎、腰椎、骶尾椎、骨盆、肩胛骨和锁骨、长骨、胸骨、肋骨及颅骨将机体骨骼分为10个区域,比较同机CT、PET及PET—CT诊断骨转移的敏感性、特异性及准确率。结果共有82例患者的331个区域被确诊为骨转移。PET—CT诊断NSCLC患者骨转移的敏感性、特异性和准确率分别为93.9%,98.9%和97.8%,高于同机CT和PET的74.4%,90.7%,87.0%和84.1%,93.2%,91.2%(P均〈0.05)。PET—CT诊断病灶骨转移的敏感性、特异性和准确性分别为98.8%、98.6%和98.7%,显著高于同机CT的79.5%、87.9%、84.5%和PET的94.3%、89.2%、91.2%,P均〈0.05。结论18F-FDGPET—CT在诊断NSCLC骨转移中优于同机CT和18F—FDGPET,对NSCLC的临床分期及治疗计划确定具有重要价值。 相似文献
4.
目的探讨^18F-脱氧葡萄糖(^18F-FDG)在诊断乳腺癌及腋窝淋巴结转移的价值。方法对34例乳腺癌患者的乳腺病灶(以健侧为对照)及腋窝淋巴结^18F-FDGPET/CT显像结果进行定性分析和半定量分析,结合病理结果,计算两种方法诊断的灵敏度、特异度、准确性。两种方法诊断与病理诊断行一致性检验。对乳腺病灶恶性组及对照组组间最大标准化摄取值(SUVmax)均数的比较采用两独立样本t检验。结果两组间SUVmax均数比较显示:恶性组^18F-FDG摄取高于对照组,差异有统计学意义(P=0.00)。1例为大汗腺导管内癌,系原位癌,对^18F-FDG摄取不明显,PET/CT图像上未见明显结节影,目测显示0级,SUVmax为1.5。该例病灶微小,小于PET/CT5~8mm的分辨率,造成定性和半定量分析均漏诊。18F-FDGPET/CT定性分析诊断乳腺癌的灵敏度、特异度、准确性分别为97.7%、100.0%、97.9%;半定量分析以suVmax2.0时,诊断乳腺癌的灵敏度、特异度、准确性为佳,分别为93.2%、100.0%、93.6%。定性分析与病理诊断的一致性极好,Kappa值为0.85,半定量分析与病理诊断有较好一致性,Kappa值为0.64。在腋窝淋巴结转移的诊断上,定性分析的诊断灵敏度、特异度、准确性分别为55.9%、96.1%、90.1%,半定量分析(以文献SUVmax1.8为标准)的诊断灵敏度、特异度、准确性分别为45.8%、97.0%、89.3%。两种分析诊断与病理诊均较好一致性,Kappa值分别为0.57(定性分析)和0.51(半定量分析)。结论^18F-FDGPET/CT诊断乳腺恶性病灶时,以SUVmax2.0为临界值进行半定量分析诊断具有较好的诊断价值;在诊断腋窝淋巴结转移方面,定性分析和半定量分析与病理诊均有较好的一致性。 相似文献
5.
目的评价^18F-脱氧葡萄糖(FDG)PET肿瘤显像与^99Tc^m-亚甲基二膦酸盐(MDP)全身骨显像诊断肿瘤骨转移价值。方法43例肿瘤患者,其中28例经其他检查或随访证实为骨转移,15例证实无骨转移。2周对患者内行^18F—FDGPET和^99Tc^m-MDP显像,比较分析两种显像结果。结果28例肿瘤骨转移患者中,^18F—FDG PET阳性26例,^99Tc^m-MDP阳性27例,灵敏度分别为92.9%(26/28)、96.4%(27/28),差异无统计学意义(P〉0.05)。15例无骨转移患者中,PET阴性14例,MDP阴性8例,特异度分别为93.3%(14/15)、53.3%(8/15),差异有统计学意义(P〈0.01)。两种方法检测骨转移的准确率分别为93.0%(40/43)、81.4%(35/43),差异有统计学意义(P〈0.01)。结论^18F—FDGPET诊断肿瘤骨转移的灵敏度与^99Tc^m-MDP显像相近,但特异性和准确性均较高。对^99Tc^m-MDP骨显像阴性、单一病灶及可疑骨转移患者,进一步行^18F—FDG PET显像,可起到信息互补、明确诊断的作用。 相似文献
6.
目的研究”氟一脱氧葡萄糖正电子发射计算机断层显像(^18F-FDGPET-CT)在寻找原发灶不明转移癌(CUP)患者原发灶中的临床价值。方法回顾性分析为寻找原发灶而行^18F-FDGPET.CT扫描的CUP患者48例,其中男28例,女20例;年龄41-82岁,平均(57±16)岁。依据转移癌部位不同将患者分为颈部淋巴结转移组(28例)及非颈部淋巴结转移组(20例),计算并比较^18F-FDGPET-CT诊断各组原发灶的灵敏度。结果^18F-FDGPET-CT寻找CUP患者原发病灶的灵敏度为66.7%(32/48),寻找颈部淋巴结转移CUP患者的灵敏度为78.6%(22/28),非颈部淋巴结转移CUP患者的灵敏度为50.0%(10/20);^18F-FDGPET-CT诊断颈部淋巴结转移组CUP患者原发灶的灵敏度与非颈部淋巴结转移组相比,差异有统计学意义(x。4.286,P〈0.05)。结论^18F-FDGPET-CT诊断CUP患者原发灶灵敏度较高,尤其适用于颈部淋巴结转移的CUP患者。、 相似文献
7.
目的:研究原发性骨淋巴瘤与单发继发性淋巴瘤骨髓浸润的18 F -FDG PET/CT 影像学表现,探讨18 F-FDG PET/CT 对原发性骨淋巴瘤的诊断及鉴别诊断价值。方法:回顾性分析经病理证实的25例单发骨淋巴瘤的18 F -FDG PET/CT 影像学资料。结果:25例骨淋巴瘤均为单发,其中14例位于脊柱骨,10例位于附肢骨,1例位于肋骨。15例为原发性骨淋巴瘤,10例为继发性淋巴瘤骨髓浸润。原发性骨淋巴瘤15例中非霍奇金淋巴瘤11例,霍奇金淋巴瘤4例;继发性淋巴瘤骨髓浸润10例中非霍奇金淋巴瘤7例,霍奇金淋巴瘤3例。25例骨淋巴瘤中23例 CT 表现为骨质密度异常改变,2例病变骨质密度未见明显异常改变。病变 FDG摄取不同程度增高,SUVmax范围为2.6~24.5。原发性骨淋巴瘤及继发性淋巴瘤骨髓浸润病变 SUVmax经 Mann-Whitney U 检验提示原发性骨淋巴瘤与继发性淋巴瘤骨髓浸润病变 SUVmax有差异(P =0.007)。结论:原发性骨淋巴瘤18 F -FDG PET/CT 影像学表现有一定的特征性,分析其表现对原发性和继发性骨淋巴瘤的诊断及鉴别诊断有一定的临床价值。 相似文献
8.
目的评价18F-FDGPET/CT对肺癌诊断及临床分期的意义。方法对来本院就诊的周围型肺部肿块患者78例,其中经病理证实的肺癌62例。18F-FDGPET/CT显像后,目测和标准摄取值(SUV)相结合判断病灶良恶性,并与病理结果对照分析。结果18F-FDGPET/CT显像对肺癌诊断的敏感性和特异性分别为88.7%和75.0%;PET/CT显像发现62例肺癌患者恶性病灶共227处;PET和CT均有肯定诊断的恶性病灶178个。结论18F-FDGPET/CT对肺癌诊断及分期有较高临床价值。结合年龄、病史及其它影像学检查进行综合判断十分重要。 相似文献
9.
目的探讨PET/CT在非小细胞肺癌纵隔淋巴结转移上的诊断价值。方法对33例术前行全身18F—FDGPET/CT检查发现肺内病灶,并行根治性手术及系统纵隔淋巴结清扫患者的PET/CT图像进行分析,记录淋巴结短径、CT值、SUVmax等,同时对患者的图像进行视觉分析,应用PET/CT综合分析法对纵隔内淋巴结进行诊断,并与病理结果对照。结果常规CT法对纵隔内淋巴结诊断的准确率为84.1%,常规PET法诊断的准确率为82.8%,常规PET/CT法对纵隔内淋巴结诊断的准确率为91.7%,PET/CT综合分析法的诊断准确率为95.2%,只有5例良性淋巴结误诊为恶性。8例肺癌伴纵隔或肺门淋巴结转移,其中5例肺癌病灶位于肺野内带。结论18F—FDGPET/CT综合分析法对纵隔淋巴结诊断的准确率较高,优于常规CT、常规PET以及常规PET/CT法()(2=15.1,P〈0.05);肺癌病灶位于肺野内带者较易发生纵隔或肺门淋巴结的转移。 相似文献
10.
目的:通过分析多发性骨髓瘤99Tcm-MDP全身骨显像与全身低剂量CT的影像表现,探讨和比较两者对多发性骨髓瘤(multiple myeloma,MM)辅助诊断、疗效监测和预后判断的应用价值。方法:回顾性分析经骨髓穿刺或手术病理证实的37例MM SPECT全身骨显像和全身低剂量CT的影像表现。结果: 37例MM患者同时行全身骨显像检查及全身低剂量CT检查,两者的阳性率分别为91.9%(34/37)、83.8%(31/37),差异无统计学意义(P>0.05);SPECT联合全身低剂量CT的阳性率为100%(37/37),较单纯SPECT及全身低剂量CT组差异均有统计学意义(P<0.05),两种方法的总一致性为86.5%。37例MM患者行SPECT检查,发现骨损害总病灶数379个,同期行全身低剂量CT检查,发现骨损害总病灶数189个,全身骨显像显示肋骨病灶的阳性率高于全身低剂量CT(P<0.05),全身低剂量CT发现颅骨(P<0.05)、四肢骨(P<0.05)和锁骨(P<0.05)病灶阳性率高于全身骨显像;而脊椎骨、骨盆、胸骨、肩胛骨在全身骨显像和全身低剂量CT上显示的病灶数目无明显差异(P>0.05)。结论:全身骨显像和全身低剂量CT对MM的诊断各有优势,均有一定的临床价值,可作为MM患者的常规检查项目。 相似文献
11.
目的:比较18F-FDG PET/CT与99Tcm-MDP骨显像对肿瘤骨转移灶的检出率,探讨两种方法在骨转移灶筛查中的价值。 方法:137例确诊恶性肿瘤患者在1月内分别进行99Tcm-MDP骨显像及18F-FDG PET/CT显像,比较分析两者对骨转移灶检出率的结果。结果:137例患者之中66例患者99Tcm-MDP骨显像为阳性,中轴骨、四肢骨均可出现,检出率为48.2%(66/137); 71例骨显像阴性患者中有12例PET/CT结果为阳性。所有患者之中62例患者18F-FDG PET/CT为阳性,检出率为45.3%(62/137),75例PET/CT阴性患者中有16例骨扫描结果为阳性。两种方法检出率之间比较(P=0.068),差异无统计学意义;按四种骨质改变类型比较两种方法检出率(P=0.173),差异无统计学意义;按CT溶骨性与成骨性类型分类比较两种方法(P=0.018),两者差异有显著性意义。结论:18F-FDG PET/CT与99Tcm-MDP骨显像筛查恶性肿瘤骨转移灶效能无明显差别,18F-FDG PET/CT优势在于发现溶骨性病变,而99Tcm-MDP骨显像的优势为成骨性改变。 相似文献
12.
目的 探讨18F-FDG PET与99Tcm-MDP显像对肿瘤骨转移的诊断价值。方法 93例肿瘤患者2周内行18F-FDG PET和99Tcm-MDP显像,比较分析两种显像结果。结果 93例肿瘤患者PET和MDP诊断骨转移64例。64例骨转移患者中PET和MDP阳性43例,PET阳性而MDP阴性16例,PET阴性而MDP阳性5例。18F-FDG PET和99Tcm-MDP显像诊断骨转移的灵敏度分别为92.2 %,75.0 %(P<0.05);特异度分别为93.1 %,79.3 %(P>0.05);准确度分别为92.5 %,76.3 %(P<0.01)。结论 18F-FDG PET诊断肿瘤骨转移的灵敏度和准确性显著高于99Tcm-MDP显像。18F-FDG PET对骨转移有一定的诊断价值。 相似文献
13.
Diagnostic Value of 18F-FDG PET/CT in Comparison to Bone Scintigraphy,CT and 18F-FDG PET for the Detection of Bone Metastasis
下载免费PDF全文
![点击此处可从《Asian Pacific journal of cancer prevention》网站下载免费的PDF全文](/ch/ext_images/free.gif)
《Asian Pacific journal of cancer prevention》2013,14(6):3647-3652
Purpose: To evaluate the diagnostic value of 18F-FDG PET/CT for detection of bone metastasis in comparisonwith the efficacies of 18F-FDG PET/CT, CT, 18F-FDG PET and conventional planar bone scintigraphy in a seriesof cancer patients. Methods: Five hundred and thirty patients who underwent both 18F-FDG PET/CT and bonescintigraphy within 1 month were retrospectively analyzed. The skeletal system was classified into 10 anatomicsegments and interpreted blindly and separately. For each modality, the sensitivity, specificity, accuracy, PPVand NPV were calculated and the results were statistically analyzed. Results: Bone metastases were confirmedin 117 patients with 459 positive segments. On patient-based analysis, the sensitivity, specificity, accuracy, PPVand NPV of 18F-FDG PET/CT were significantly higher than bone scintigraphy, CT and 18F-FDG PET (P<0.05).On segment-based analysis, the sensitivity of CT, bone scintigraphy, 18F-FDG PET and 18F-FDG PET/CT were70.4%, 89.5%, 89.1% and 97.8%, respectively (P<0.05, compared with 18F-FDG PET/CT). The overall specificityand accuracy of the four modalities were 89.1%, 91.8%, 90.3%, 98.2% and 90.3%, 90.9%, 89.8%, 98.0%,respectively (P<0.05, compared with 18F-FDG PET/CT). The PPV and NPV were 89.8%, 87.6%, 85.6%, 97.2%and 85.6%, 93.2%, 92.8%, 98.6%, respectively. Three hundred and twelve lesions or segments were presentedas lytic or sclerotic changes on CT images at the corresponding sites of increased 18F-FDG uptake. In lytic ormixed lesions, the sensitivity of 18F-FDG PET/CT and 18F-FDG PET were better than bone scintigraphy, whilein osteoblastic lesions bone scintigraphy had a similar performance with 18F-FDG PET/CT but better than18F-FDG PET alone. Conclusion: Our data allow the conclusion that 18F-FDG PET/CT is superior to planar bonescintigraphy, CT or 18F-FDG PET in detecting bone metastasis. 18F-FDG PET/CT may enhance our diagnosis oftumor bone metastasis and provide more information for cancer treatment. 相似文献
14.
《Annals of oncology》2015,26(10):2113-2118
BackgroundThe detection of occult bone metastases is a key factor in determining the management of patients with renal cell carcinoma (RCC), especially when curative surgery is considered. This prospective study assessed the sensitivity of 18F-labelled sodium fluoride in conjunction with positron emission tomography/computed tomography (18F-NaF PET/CT) for detecting RCC bone metastases, compared with conventional imaging by bone scintigraphy or CT.Patients and methodsAn adaptive two-stage trial design was utilized, which was stopped after the first stage due to statistical efficacy. Ten patients with stage IV RCC and bone metastases were imaged with 18F-NaF PET/CT and 99mTc-labelled methylene diphosphonate (99mTc-MDP) bone scintigraphy including pelvic single photon emission computed tomography (SPECT). Images were reported independently by experienced radiologists and nuclear medicine physicians using a 5-point scoring system.ResultsSeventy-seven lesions were diagnosed as malignant: 100% were identified by 18F-NaF PET/CT, 46% by CT and 29% by bone scintigraphy/SPECT. Standard-of-care imaging with CT and bone scintigraphy identified 65% of the metastases reported by 18F-NaF PET/CT. On an individual patient basis, 18F-NaF PET/CT detected more RCC metastases than 99mTc-MDP bone scintigraphy/SPECT or CT alone (P = 0.007). The metabolic volumes, mean and maximum standardized uptake values (SUVmean and SUVmax) of the malignant lesions were significantly greater than those of the benign lesions (P < 0.001).Conclusions18F-NaF PET/CT is significantly more sensitive at detecting RCC skeletal metastases than conventional bone scintigraphy or CT. The detection of occult bone metastases could greatly alter patient management, particularly in the context when standard-of-care imaging is negative for skeletal metastases. 相似文献
15.
目的:评价18F-脱氧葡萄糖(18F-fluorodeoxyglucose,18F-FDG)PET/CT显像在肾上腺肿瘤诊断中的应用价值。方法:回顾性分析42例肾上腺肿瘤患者的全身18F-FDG PET/CT及CT平扫加增强的影像学资料,比较两者对肾上腺肿瘤的诊断价值。结果:42例中,原发性肾上腺肿瘤30例,均经手术病理证实。其余12例为转移性肾上腺肿瘤,肾癌转移4例,肺癌转移7例,肝癌转移1例。18F-FDG PET/CT检查阳性42例,敏感度100%,良性病变的SUV值为1.1-2.6,平均1.8,恶性病变的SUV值为2.5-12.3,平均6.0。良恶性病变的SUV值差异有统计学意义(P〈0.01)。CT平扫加增强检查阳性38例,敏感度90.5%。PET/CT对肾上腺肿瘤的敏感度明显高于CT,两者差异有统计学意义(P〈0.05)。结论:18F-FDG PET/CT在肾上腺肿瘤诊断中具有重要价值,敏感度高于CT。 相似文献
16.
目的评价^18F-脱氧葡萄糖(^18F-FDG)正电子发射断层扫描(PET)-CT显像及CT灌注扫描显示乳腺癌代谢、血流特点的价值。方法32例未治疗的乳腺肿块患者,分别行PET-CT检查和CT强化扫描。所有病灶在10d内经手术切除或活检行病理组织学检查。18F-FDGPET-CT显像经半量化分析,用灌注3软件包处理CT灌注扫描图像,将两种影像学检查结果与病理诊断进行比较研究。结果良性病变和乳腺癌的^18F-FDG标准摄取值(SUV)差异具有统计学意义(P〈0.05),乳腺癌中心和周边的^18F-FDG的SUV差异也具有统计学意义(P〈0.05);^18F-FDG的摄取与乳腺癌病理类型和分级有关。CT灌注扫描显示血流(BF)、血量(BV)和表面渗透(Ps)在乳腺癌和正常组织中差异具有统计学意义(t=8.0650,P〈0.0001;t=2.7691,P=0.0115;T^+=253.0000,T-=0.0000,P〈0.0001),乳腺肿瘤周边区和中心区BF、BV和PS灌注值平均差也具有统计学意义(t=8.0158,P〈0.0001;t=2.2434,P=0.0179;t=3.4857,P=0.0022)。结论^18F-FDGPET-CT显像及CT灌注扫描可以很好的显示乳腺癌的代谢和血流灌注特征,从而间接反映乳腺癌的生物学特征,对乳腺癌的诊断和预后评估具有重要的临床价值。 相似文献
17.
目的:对比研究^(131)I-MIBG显像、^(18)F-FDG PET/CT显像与^(99)Tc^(m)-MDP-WBS多模态显像在嗜铬细胞瘤/副神经节瘤(PCC/PGL)骨转移病灶中的诊断价值。方法:回顾性分析本院收治的PCC/PGL患者共30例,所有患者均伴骨转移且已行以上三种检查(检查的时间间隔为3个月内)。以病理、影像学检查及临床随访结果作为骨转移的诊断依据。比较三种检查方法检测PCC/PGL骨转移病灶的灵敏度、特异性、阳性及阴性预测值和准确性。使用SPSS 25.0软件分析,采用McNemar检验比较三种检查方法诊断骨转移的价值。结果:30例PCC/PGL患者共检查出骨异常病灶302处,确诊为骨转移病灶271处。^(131)I-MIBG显像、^(18)F-FDG PET/CT显像与^(99)Tc^(m)-MDP-WBS在诊断PCC/PGL骨转移病灶时的灵敏度、特异性、阳性和阴性预测值及准确性分别是92.00%、96.30%、99.60%、54.17%、92.38%;96.00%、92.59%、99.25%、69.44%、95.70%和88.39%、62.86%、94.78%、41.51%、85.43%。三种检查方法在诊断PCC/PGL骨转移病灶时^(18)F-FDG PET/CT显像灵敏度最高,^(131)I-MIBG显像特异性最好。三种检查方法的诊断效能经McNemar检验,差异有统计学意义(P<0.05)。结论:^(131)I-MIBG显像可作为PCC/PGL骨转移的首选检查方法并指导后续^(131)I-MIBG治疗,^(18)F-FDG PET/CT显像和^(99)Tc^(m)-MDP-WBS可作为可疑病灶^(131)I-MIBG显像阴性时的有效补充。 相似文献
18.
Impact of combined (18)F-FDG PET/CT in head and neck tumours 总被引:11,自引:0,他引:11
Syed R Bomanji JB Nagabhushan N Hughes S Kayani I Groves A Gacinovic S Hydes N Visvikis D Copland C Ell PJ 《British journal of cancer》2005,92(6):1046-1050
To compare the interobserver agreement and degree of confidence in anatomical localisation of lesions using 2-[fluorine-18]fluoro-2-deoxy-D-glucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) and (18)F-FDG PET alone in patients with head and neck tumours. A prospective study of 24 patients (16 male, eight female, median age 59 years) with head and neck tumours was undertaken. (18)F-FDG PET/CT was performed for staging purposes. 2D images were acquired over the head and neck area using a GE Discovery LS PET/CT scanner. (18)F-FDG PET images were interpreted by three independent observers. The observers were asked to localise abnormal (18)F-FDG activity to an anatomical territory and score the degree of confidence in localisation on a scale from 1 to 3 (1=exact region unknown; 2=probable; 3=definite). For all (18)F-FDG-avid lesions, standardised uptake values (SUVs) were also calculated. After 3 weeks, the same exercise was carried out using (18)F-FDG PET/CT images, where CT and fused volume data were made available to observers. The degree of interobserver agreement was measured in both instances. A total of six primary lesions with abnormal (18)F-FDG uptake (SUV range 7.2-22) were identified on (18)F-FDG PET alone and on (18)F-FDG PET/CT. In all, 15 nonprimary tumour sites were identified with (18)F-FDG PET only (SUV range 4.5-11.7), while 17 were identified on (18)F-FDG PET/CT. Using (18)F-FDG PET only, correct localisation was documented in three of six primary lesions, while (18)F-FDG PET/CT correctly identified all primary sites. In nonprimary tumour sites, (18)F-FDG PET/CT improved the degree of confidence in anatomical localisation by 51%. Interobserver agreement in assigning primary and nonprimary lesions to anatomical territories was moderate using (18)F-FDG PET alone (kappa coefficients of 0.45 and 0.54, respectively), but almost perfect with (18)F-FDG PET/CT (kappa coefficients of 0.90 and 0.93, respectively). We conclude that (18)F-FDG PET/CT significantly increases interobserver agreement and confidence in disease localisation of (18)F-FDG-avid lesions in patients with head and neck cancers. 相似文献